熱門資訊> 正文

Climb Bio任命道格拉斯·威廉姆斯为主席

2024-11-11 20:11

Climb Bio (NASDAQ:CLYM) said it has appointed Douglas Williams as its chair.
Williams will succeed Andrew Levin in the role.
Williams has over 30 years of executive leadership experience in the biotechnology sector, and formerly served as the president of research and development at Sana Biotechnology and was CEO of Codiak BioSciences.

More on Climb Bio

Eliem Therapeutics: Recent Strategic Pipeline Restructuring
Eliem Therapeutics rebrands as Climb Bio with new name and logo
Eliem Therapeutics appoints Kaplan as COO; Rampal as SVP, Clinical Development

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。